8 matokeo
DESCRIPTION
BACKGROUND OF THE INVENTION
The present invention provides a new use for some known compounds. More particularly, the present invention provides a method for preventing renal papillary necrosis induced by non-steroidal anti-inflammatory compounds (NOSAC) by the administration of certain
TECHNICAL FIELD
The present invention relates to (1) a pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub.4 agonist as an active ingredient, (2) a sustained release formulation comprising the
TECHNICAL FIELD
The present invention relates to (1) a pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub.4 agonist as an active ingredient, (2) a sustained release formulation comprising the
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to a composition for maturing dendritic cells, and a method for preparing antigen-specific dendritic cells using the same.
2. Description of the Related Art
Dendritic cells (DCs) are antigen-presenting cells (APCs) that
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to extract of adlay bran and uses thereof; more particularly, the uses in treating a skin and/or subcutaneous tissue disease and lowering interleukin (IL)-1.alpha., interleukin-1.beta., interleukin-6, tumor necrosis factor
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to extract of adlay bran and uses thereof; more particularly, the uses in treating a skin and/or subcutaneous tissue disease and lowering interleukin (IL)-1.alpha., interleukin-1.beta., interleukin-6, tumor necrosis factor
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to extract of adlay bran and uses thereof; more particularly, the uses in treating a skin and/or subcutaneous tissue disease and lowering interleukin (IL)-1.alpha., interleukin-1.beta., interleukin-6, tumor necrosis factor
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/KR2010/003239, filed on May 24, 2010, which claims the benefit of Korean Patent Application Nos. 10-2009-0044900, filed on May 22, 2009, and 10-2010-0029016, filed on Mar. 31, 2010, the contents of each of which are